Comparing Two Palliative Schemes of Radiotherapy for Head and Neck Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-11-30

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

RCT to compare two radiation schemes for palliative HeadNeck cancer

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

SBRT + Immunomodulating Systemic Therapy for Inoperable, Recurrent H&N

NCT03402737

Head and Neck Neoplasm

TERMINATED NA

Review of Palliative Radiotherapy in the Management of Advanced Head and Neck Cancer

NCT00280891

Head and Neck Cancer

COMPLETED

Palliative Radiotherapy Protocol in Head and Neck Cancer

NCT02460471

Head and Neck Neoplasms Quality of Life

COMPLETED PHASE2

Outcome Prediction in Head&Neck Cancer Patients After Radiotherapy

NCT01985984

Head and Neck Cancer

RECRUITING

DAHANCA 20 Palliative Radiotherapy for Head and Neck Cancer

NCT00400426

Head and Neck Neoplasms Recurrence Neoplasms, Second Primary

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A substantial proportion of patients with head and neck (HNC) are not suitable for curative treatment with surgery and/or (chemo)radiotherapy (CRT) because of very advanced stage, significant comorbidities, bad general condition, distant metastasis, or a combination of these factors. Although radiotherapy (RT) is a commonly used option to achieve durable disease control and to alleviate troublesome symptoms, the data about the optimal radiation scheme and the impact of these schedules on quality of life (QoL) of these vulnerable patients is extremely scarce.

Although different radiation schemes are used worldwide (in the Netherlands, at least 15 different radiation schedules are used), it is currently not possible to identify the best RT scheme, based only on retrospective studies because of the major differences between these studies with regard to patient's demographics, radiation schedules given, the radiation technique used etc. Furthermore, no any information is available on the impact of these schemes on treatment-related toxicity and QoL.

This illustrates the urgent need for a multicenter randomized controlled trial (RCT) to identify the most optimal schemes of RT for this group of patients. Therefore, the investigators intend to initiate a prospective RCT comparing the survival, loco-regional control, toxicity, and QoL of two commonly used schemes. This study will be the first of his kind for palliative patients with HNC and will compare a short-course (6 fractions) with a long-course of radiotherapy (16 fractions). Because most of patients with incurable HNC have a poor performance status and major comorbidity and prefer limited number of visits to the hospital, it is quite reasonable to investigate whether a short scheme of radiotherapy with limited number of visits to the clinic as good as a relatively long-course of radiotherapy in terms of outcome, toxicity and QoL. This delicate balance between outcomes, possible toxicity and patient's comfort would justify the initiation of such randomized trial. The results of this study will in the nearby future enable us to indicate the radiation scheme best suits which patient category

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Head and Neck Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

arm 1: 6 fractions of radiation

radiation in a 6 fractions scheme and a daily dose of 6 Gy

Group Type ACTIVE_COMPARATOR

6 x 6 Gy

Intervention Type RADIATION

radiation in 6 fraction of 6 Gy, twice a week during 3 weeks

arm 2: 16 fractrions of radiation

radiation in a 16 fractions scheme and a daily dose of 3.125 Gy

Group Type ACTIVE_COMPARATOR

16 x 3.125 Gy

Intervention Type RADIATION

radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

6 x 6 Gy

radiation in 6 fraction of 6 Gy, twice a week during 3 weeks

Intervention Type RADIATION

16 x 3.125 Gy

radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

• Newly diagnosed patients with primary non-metastatic carcinoma located in the oral cavity, oropharynx, larynx (except T1 glottic), hypopharynx, nasopharynx, paranasal sinuses and salivary gland and carcinoma of unknown primary in the head and neck region who are not suitable for radical treatment with surgery or (chemo) and, therefore, planned for treatment with radiotherapy in palliative setting.

OR

* Newly diagnosed patients with primary head and neck carcinoma with limited metastatic disease in a good general condition and few comorbidities (ACE-25 \<3) with life expectancy of at least 6 months are also eligible.
* No chemotherapy or surgery is allowed before inclusion.
* Age ≥ 18 years
* WHO performance status 0-2
* Signed written informed consent

Exclusion Criteria

* Patients with previously radiation treatment in the head and neck region, for any reason.

\* Chemotherapy or surgery for head and neck tumor before inclusion and no other concomitant anti-cancer therapy is allowed during study treatment.
* Patients with head and neck malignancies arising from skin, nose, thyroid gland or esophagus.
* Patients with advanced stage sarcoma or lymphoma of the head and neck region.
* Expected life expectancy of less than 3 months

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No